The Melanoma and Advanced Skin Cancer Program strives to improve patient outcomes through projects that span the spectrum between basic, translational, and clinical research. Our doctors work closely with scientists, with the hope of using our basic and translational research findings to improve the treatments and the clinical outcomes of our patients with advanced skin cancers.
Our physicians include a multi-disciplinary team of dermatologists, as well as surgical, radiation and medical oncologists. Our team has dedicated expertise and is experienced in specialized treatment for melanoma as well as advanced cutaneous squamous cell, basal cell, and merkel cell carcinomas. We seek to individualize treatment based on a patient’s needs and offer a wide array of clinical trials to provide access to the latest therapies.
Treatment options for patients with melanoma have rapidly expanded in recent years, with some of the biggest advances coming in the development of new immunotherapies. However, despite this promise, many patients with advanced melanoma do not respond to the medications that are currently available. As a result, one of our primary translational research goals is to better understand how melanomas develop resistance to these types of agents. We believe that a fundamental understanding of these mechanisms will lead to the identification of novel immunotherapy strategies as well as the discovery of biomarkers capable of improving the management of patients with advanced melanoma.
With this goal in mind, we are currently using pre-clinical models as well as clinical tissue specimens to investigate these questions and to develop novel immunotherapy approaches for patients with melanomas that have been refractory (resistant) to standard treatment. This work includes projects to identify pharmacological targets capable of enhancing the activity of and overcoming resistance to checkpoint inhibitor immunotherapy and other initiatives using captured circulating melanoma cells to detect markers of immunotherapy resistance.
In another example of a novel approach, DCI scientists are working in the lab to develop therapies that stimulate immune responses that target and kill melanoma cells by releasing tumor antigens and activating immune cells that infiltrate the tumor. To achieve these goals, basic research scientists and clinical investigators within the program collaborate closely to generate a clinically meaningful impact on our patients with advanced skin cancer.
For more information on Tumor Immunology and Immunotherapy, visit:
* SWOG S1404: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
* A Phase I trial of Neoadjuvant Nivolumab and Ipilimumab followed by Melphalan via Isolated Limb Infusion for Patients with Unresectable In-transit Extremity Melanoma
* An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
* A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy
* A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody -Drug Conjugate, in Patients with Advanced Melanoma
* A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melanoma
Uveal Melanoma Trials
* A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma
To make an appointment, please call 888.275.3853. For more information on skin cancer care at Duke Health, visit:
To find a doctor, visit Find A Specialist.
Tricia Gallagher was 43 when she felt something like a scab on her head. She didn’t think much of it. Her doctor in Winston-Salem told her it was melanoma. After three unsuccessful surgeries and radiation, she still wasn't cancer-free. Her doctors there sent her to Duke. That’s when she met Brent Hanks, MD, PhD, her "dragon slayer." MORE
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More